Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer

Sponsor
Adam S. Kibel, MD
Status
Recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT06398639
The goal of this clinical trial is to evaluate a screening method to detect clinically relevant prostate cancer. This clinical trial is using genetic data to determine a man's risk of cancer, together with multiparametric magnetic resonance imaging (mpMRI) to identify men with higher grade cancer.

The main questions it aims to answer are:

* If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer
* What age a MRI is useful clinically for prostate cancer screening
* If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers

Participants will:

* Get a prostate specific antigen (PSA) blood test
* Get an mpMRI
* Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing
* Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI
Intervention
Polygenic Risk Score (PRS)
Condition
Prostate Cancer, Polygenic Risk Score
Investigators
Adam S Kibel, MD, MHCM, Peter Pinto, MD, Peter L Choyke, MD, FACR, Tamaro S Hudson, PhD, MPH, Pamela Coleman, MD, Peter A Pinto, MD, Gregory T Chesnut, MD, Ismail B Turkbey, MD

See list of participating sites